BONTAGRRO Trademark

Serial Number: 99820854

BONTAGRRO is a trademark filed by Hong Kong King-Friend, Industrial Company, Ltd. on May 13, 2026. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Trademark Classes

5

Class 5 - Pharmaceuticals

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Owner Contact Info

Hong Kong King-Friend, Industrial Company, Ltd. (6 trademarks)

Room 2808, 28/F Omega Plaza, 32 Dundas St.
Hong Kong , HK

Entity Type: 16

Legal Representation

Attorney of Record

Eric R. Moran

2,272 trademarks filed View all →

Correspondence Address

Eric R. Moran McDonnell Boehnen Hulbert & Berghoff LLP

300 South Wacker Drive

31st Floor

Chicago, IL 60606

United States

Trademark Details

Filing Date

May 13, 2026

Registration Date

Not Registered

Goods & Services

Pharmaceuticals; pharmaceutical preparations; pharmaceutical products; biologics; biosimilars; filgrastim biosimilars; pharmaceutical preparations for the treatment of neutropenia; pharmaceutical preparations for the treatment of low white blood cells; pharmaceutical preparations for use in stimulating white blood cell production; biosimilars for use in stimulating white blood cell production; pharmaceutical preparations, namely, recombinant-human granulocyte-CSF for use in stimulating white blood cell production; recombinant-human granulocyte-CSF biosimilars for use in stimulating white blood cell production; pharmaceutical preparations, namely, injectable filgrastim biosimilars; pharmaceutical preparations, namely, injectable biosimilars for the treatment of neutropenia; pharmaceutical preparations, namely, injectable biosimilars for the treatment of low white blood cells; pharmaceutical preparations, namely, injectable biosimilars for use in stimulating white blood cell production; pharmaceutical preparations, namely, injectable recombinant-human granulocyte-CSF for use in stimulating white blood cell production; pharmaceutical preparations, namely, injectable recombinant-human granulocyte-CSF biosimilars for use in stimulating white blood cell production; injectors sold filled with filgrastim biosimilars; injectors sold filled with pharmaceutical preparations for the treatment of neutropenia; injectors sold filled with pharmaceutical preparations for the treatment of low white blood cells; injectors sold filled with pharmaceutical preparations for use in stimulating white blood cell production; injectors sold filled withbiosimilars for use in stimulating white blood cell production; injectors sold filled with recombinant-human granulocyte-CSF for use in stimulating white blood cell production; injectors sold filled with recombinant-human granulocyte-CSF biosimilars for use in stimulating white blood cell production